Literature DB >> 9986878

Evaluation of the fungitest kit by using strains from human immunodeficiency virus-infected patients: study of azole drug susceptibility.

F Witthuhn1, D Toubas, I Béguinot, D Aubert, C Rouger, G Remy, J M Pinon.   

Abstract

One hundred eighteen Candida clinical isolates from human immunodeficiency virus-infected patients were tested for their susceptibilities to fluconazole and itraconazole by Fungitest and the National Committee for Clinical Laboratory Standards MIC method. Fungitest results depended on both yeast species and antifungal agents. This test is able to detect sensitive strains (97% agreement with results of the MIC method in tests with fluconazole and 84% agreement in tests with itraconazole) but has a poor capacity to detect resistant strains (26% agreement in tests with fluconazole and 5% agreement in tests with itraconazole).

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9986878      PMCID： PMC84589     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  15 in total

Review 1.  Fluconazole, a new antifungal agent.

Authors:  J N Galgiani
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

Review 2.  Is antifungal susceptibility testing useful in guiding fluconazole therapy?

Authors:  M A Ghannoum
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

3.  Rapid detection of susceptibility to fluconazole in Candida species by a bioluminescence assay of intracellular ATP.

Authors:  M Kretschmar; T Nichterlein; P Kuntz; H Hof
Journal:  Diagn Microbiol Infect Dis       Date:  1996-07       Impact factor: 2.803

4.  Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing.

Authors:  A L Colombo; F Barchiesi; D A McGough; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

5.  Itraconazole cyclodextrin solution--effective treatment for HIV-related candidosis unresponsive to other azole therapy.

Authors:  J D Cartledge; J Midgley; M Youle; B G Gazzard
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

6.  Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans.

Authors:  F Laguna; J L Rodríguez-Tudela; J V Martínez-Súarez; R Polo; E Valencia; T M Díaz-Guerra; F Dronda; F Pulido
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

7.  Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients.

Authors:  S G Revankar; W R Kirkpatrick; R K McAtee; O P Dib; A W Fothergill; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

8.  The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts.

Authors:  D W Feigal; M H Katz; D Greenspan; J Westenhouse; W Winkelstein; W Lang; M Samuel; S P Buchbinder; N A Hessol; A R Lifson
Journal:  AIDS       Date:  1991-05       Impact factor: 4.177

9.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.

Authors:  M Ruhnke; A Eigler; I Tennagen; B Geiseler; E Engelmann; M Trautmann
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

10.  Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.

Authors:  J R Maenza; J C Keruly; R D Moore; R E Chaisson; W G Merz; J E Gallant
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226
View more
  4 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Trends in antifungal susceptibility among Candida sp. Urinary isolates from 1994 and 1998.

Authors:  J Baran; E Klauber; J Barczak; K Riederer; R Khatib
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico.

Authors:  Luis Octavio Sánchez-Vargas; Natalia Guadalupe Ortiz-López; María Villar; María Dolores Moragues; José Manuel Aguirre; Miguel Cashat-Cruz; Jose Luis Lopez-Ribot; Luis Alberto Gaitán-Cepeda; Guillermo Quindós
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

4.  Retrospective observation of drug susceptibility of Candida strains in the years 1999, 2004, and 2015.

Authors:  Cecylia Łukaszuk; Elżbieta Krajewska-Kułak; Wojciech Kułak
Journal:  PeerJ       Date:  2017-02-23       Impact factor: 2.984
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.